U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Vaccines, Blood & Biologics
  3. Cellular & Gene Therapy Products
  4. OTP Type D Meetings
  1. Cellular & Gene Therapy Products

OTP Type D Meetings

Type D Meetings should be limited to one or two focused topics, should not exceed three to five questions in total, and should not require input from more than three disciplines or divisions.  If the sponsor has more than two focused topics, a highly complex issue is raised, or a follow-up question that raises a new issue after a formal meeting (i.e., more than just a clarifying question about an FDA response from a prior meeting), then a Type B or C Meeting should be considered instead of a Type D Meeting. A Type B or C Meeting should also be scheduled in lieu of multiple Type D Meetings scheduled in temporal proximity. 

Type D Meeting requests are evaluated on a case-by-case basis to determine if the meeting meets the criteria for the meeting type.


Submission of Type D Meeting Requests to OTP

Type D Meetings may be requested at any stage of development and should be submitted as an amendment under the Pre-IND, IND, or BLA. The meeting request should include a list of the specific objectives of the meeting and a list of questions.

OTP does not send an acknowledgement email or letter following OTP’s receipt of a meeting request. However, by the timelines described in Table 9 , OTP will send the decision to grant or deny the meeting request, along with the meeting date, if granted, or reasons for denial.

Table 9: Timelines for Type D Meetings

OTP Response to Meeting Request**

14 days

Meeting Scheduling or WRO issued***

50 days

Meeting Package Due to OTP

At the time of the meeting request

Meeting Length

60 minutes

OTP Preliminary Response to Questions in the Package to Sponsor

NLT* 5 days before the meeting

Sponsor’s Response to FDA Preliminary Response

NLT 3 days after receipt of Preliminary Responses

*NLT – No Later Than
SourceTable 9 information from the Formal Meetings Between the FDA & Sponsors or Applicants of PDUFA Products Guidance for Industry
**Calendar days from FDA receipt of the meeting request to the date that OTP will respond with the decision to grant or deny the meeting, as well as specifying the format and date of the meeting, if granted.
*** Calendar days from FDA receipt of the meeting request to date the meeting will be held, or the WRO will be issued.

 

Back to Top